Observational studyBMJ open respiratory research2023
Burden of COPD in China and the global from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019.
Observational study in BMJ open respiratory research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 34 citations in OpenAlex.
- Application value of the impulse oscillometry system in the airway evaluation of patients with chronic obstructive pulmonary disease in different age groups.Internal medicine journal · 2026Article
- COPD burden trends in China and G20 countries from GBD 2023 and Mendelian randomization.iScience · 2026Article
- Efficacy of Liuzijue in Improving Respiratory Muscle Dysfunction in Chronic Obstructive Pulmonary Disease: Protocol for a Randomized Controlled Trial.JMIR research protocols · 2026Article
- Inhaled corticosteroid overuse and deprescribing eligibility in COPD (iCODEC Study): a nationwide cross-sectional analysis in China.NPJ primary care respiratory medicine · 2026Article
- Article
- COPD in China: the analysis of mortality and burden of disease trends from 2008 to 2021.Respiratory research · 2026Article
- Temporal and Partial Reversal of Airflow Limitation in Patients With COPD Treated With Single-Inhaler Long-Acting Dual Bronchodilators.The clinical respiratory journal · 2026Article
- Diagnostic and prognostic value of serum miR-155 in chronic obstructive pulmonary disease.Scientific reports · 2026Article
- Association between depression and chronic lung diseases in older Chinese adults: a national cross-sectional study.BMC public health · 2026Article
- The contributions of active and passive smoking to COPD-related mortality and DALYs in the context of COVID-19: Global Burden 2019-2021.Tobacco induced diseases · 2026Article
- Disability in Older Adults with COPD: Prevalence, Assessment, and Influencing Factors - A Scoping Review.Clinical interventions in aging · 2026Article
- Effectiveness of an Internet-Based 4C Nursing Model on Pulmonary Rehabilitation Outcomes in Patients with Chronic Obstructive Pulmonary Disease: A Quasi-Experimental Study.Patient preference and adherence · 2026Article
- Exposure-response relationship between ambient PMFrontiers in public health · 2026Article
- Article
- The Multidimensional Burden of COPD in China: A Propensity Score-Matched Comparison with Other Prevalent Non-Communicable Diseases.International journal of chronic obstructive pulmonary disease · 2026Article
- Epidemiological Trends and Projections of PMInternational journal of chronic obstructive pulmonary disease · 2026Article
- Association of loneliness trajectories with chronic obstructive pulmonary disease, a cohort study from China.NPJ primary care respiratory medicine · 2025Article
- Article
- Management of COPD With Cardiovascular Risk in Asia: A Review by the Asian Pacific Society of Respirology COPD Assembly.Respirology (Carlton, Vic.) · 2025Review
- Pulmonary hypertension aetiologies in different parts of the world.International journal of cardiology. Congenital heart disease · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the current disease burden of chronic obstructive pulmonary disease (COPD) in China and globally using the Global Burden of Disease (GBD) data in 2019, as well as to analyse the changes in its risk factors, providing a scientific basis for the formulation of a comprehensive prevention and control strategy for COPD in China. STUDY
designAn observational study based on the GBDs.
methodsBased on the GBD 2019 database, we obtained data on incidence, prevalence, mortality, disability-adjusted life years (DALYs) and corresponding age-standardised rates of COPD in China and the global, and analysed and described the changing trends of COPD burden in China and the global from 1990 to 2019.
resultsIn 2019, the total number of COPD deaths in China was 1.04 (95% uncertainty intervals (95% UI): 0.89-1.27) million cases, the number of patients with COPD was 45.16 (95% UI: 41.13-49.62) million cases, and the number of new cases was 4.0 (95% UI: 3.6-4.4) million cases. DALYs were 74.4 (95% UI: 68.2-80.2) million years. Compared with 1990, the number of new incident cases and the overall prevalence of COPD in China in 2019 increased by 66.20% and 66.76%, respectively, which is lower than the overall global level.
conclusionFrom 1990 to 2019, the age-standardized prevalence rate (ASPR), the age-standardized incidence rate (ASIR) and the age-standardized death rate (ASDR) in China and the global all showed a downward trend, and the rate of decline in China was much higher than the overall level of the world, indicating that China has made specific achievements in the prevention and treatment of COPD, but overall the disease burden of COPD is still hefty, and the number of affected individuals is still increasing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.